Author name: admin

Navnath Karche, PhD, a Medicinal Chemist with over 18 years of experience across multiple discovery programs in Oncology, Metabolic Disorders, and CNS therapeutic areas. Navnath previously worked at Dai-Ichi and Lupin, after his PhD from Pune University and post-doc from Rouen, France. Ganesh Gudade, with over 20 years of MedChem experience at Lupin, Glenmark and […]

Srikant Viswanadha, an accomplished industry leader, has joined Satya as its CSO. Srikant has over 19 years’ pharmaceutical experience in reputed companies, and has been involved in the discovery and early clinical development of multiple programs. He was last the CSO at Incozen/ Rhizen. Manoj Pothuganti has also joined Satya as a Program Lead and

Satya is attending the ASCO Annual Meeting between June 3-6, 2022 at Chicago, IL.

Satya is expanding its lab infrastructure and team size at its facilities in Hyderabad, India to add additional discovery programs to the pipeline. Upon completion, the lab size would double and the company can run up to six discovery programs in parallel.

Poster 6368: “Discovery of potent, orally bioavailable, SOS1 inhibitors for KRAS-driven tumors” Abstract   KRAS is an oncogene implicated in a wide variety of tumors (~21% of solid tumors harbor KRAS mutations). KRAS interaction with Guanidine Exchange Factors (GEFs) is crucial for its activation, with SOS1 being the predominant GEF. SOS1 inhibition is thus expected

Poster #LBA041: AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer, October 7-10, 2021 The DNA damage response (DDR) is a complex cellular network that acts as a cell defense mechanism and exerts signal for repair of DNA lesions. It repairs different types of DNA damage such as single-strand (ssDNA) breaks, DNA inter-strand crosslinks and

Satya has taken incubation space at the AIC-CCMB campus in Hyderabad; the incubation space provides access to world-class biology infrastructure, as well as expertise available at CCMB, a premier biology institution of India Satya will have its senior scientists working out of the incubation centre, and would be able to conduct a number of advanced

Dr. John Bondo Hansen is a seasoned Medicinal Chemist and formally Vice President of Medicinal Chemistry at Novo Nordisk. Dr. Hansen worked in drug discovery in positions of increasing responsibility. He was the co-founder and member of management of several companies including Contera Pharma, which was acquired by Bukwang Pharma of Korea in 2014.

Satya announced presentation of poster on Preclinical data for its SOS1 inhibitor program SAT101 at the AACR 2021. Poster Title: Identification of novel SOS1-K-Ras disruptors for NSCLC and colon cancers with K-Ras mutation. Poster Title: Identification of novel SOS1-K-Ras disruptors for NSCLC and colon cancers with K-Ras mutation. Poster number: LB117 April 10, 2021 Saturday

Satya has inaugurated its new R&D facilities in Hyderabad, comprising Medicinal Chemistry, Biochemistry, Cell and assay biology labs on March 15, 2021. Satya @ JPM Satya is at JPM 2013 in SFO (Jan 9-12, 2023). Please contact murthycsn@satyarx.com, to set up a meeting